Omega: Flagship’s latest venture into the chromatin white space
Omega’s launch deepens Flagship’s investment in chromatin structure-based gene control
Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level.
With a platform that homes in on the structural elements surrounding individual or small groups of genes, the company may be able to selectively regulate gene expression across a broad swath of indications.
Founded in 2017 in Flagship Pioneering’s Flagship Labs incubator, Omega Therapeutics Inc. launched